FULC: Fulcrum to merge with Slate Medicines in stock deal
Fulcrum to merge with Slate Medicines via reverse merger; Slate holders get Fulcrum shares, options cancelled above $7.00, pending…
What this filing says
Fulcrum Therapeutics and Slate Medicines agreed on August 16, 2026 to combine through a two-step merger, with Slate becoming a wholly owned subsidiary and Fulcrum renamed Slate Medicines, Inc. Fulcrum stockholders must approve the deal and related share issuance, which is subject to closing conditions not yet met. Because Slate holders will receive new Fulcrum shares, existing Fulcrum holders could see their ownership diluted.
Key figures
- Merger agreement date
- August 16, 2026
- Stock option cancellation threshold
- $7.00 per share
- Share issuance threshold noted
- 20% of outstanding Fulcrum common stock
Positive for shareholders
- Fulcrum stockholders are asked to vote on the transaction, giving them a say before it closes.
- Unvested Fulcrum restricted stock units will be accelerated in full at the effective time.
Negative for shareholders
- Slate stockholders will receive Fulcrum shares, which would increase the number of shares outstanding.
- The merger will not occur unless Fulcrum stockholders approve it and other closing conditions are met.
- Fulcrum stock options priced above $7.00 per share will be cancelled for no consideration.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Reverse stock split:
- A corporate action that reduces the number of outstanding shares by combining them, which typically raises the per-share price.
- Exchange Ratio:
- The formula that sets how many Fulcrum shares each Slate share converts into in the merger.
- Surviving corporation:
- The company that continues to exist after a merger, absorbing the other company.
FAQ
What will Fulcrum stockholders need to do?
Fulcrum stockholders are asked to vote on Proposal No. 1, which covers approving the merger and related share issuance.
Will Fulcrum change its name?
Yes, the filing states that Fulcrum will change its corporate name to Slate Medicines, Inc. after the merger.
What happens to Fulcrum's existing shares?
Shares outstanding at the first effective time remain outstanding and are unaffected by the merger, subject to the proposed reverse stock split.
Historical context for FULC
Across the 20 sessions after earlier FULC headlines, the stock closed higher 9 times and lower 11 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Follow FULC and get a push notification the moment its next story breaks.